投稿咨詢
Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.
The Editors welcome:
Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies
Drug Evaluations reviewing the clinical and pharmacological data on a particular drug
Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
《Expert Opinion On Investigational Drugs》是一本由TAYLOR & FRANCIS LTD出版商出版的專業醫學期刊，該刊創刊于1994年，刊期Monthly，該刊已被國際權威數據庫SCIE收錄。在中科院最新升級版分區表中，該刊分區信息為大類學科：醫學 2區，小類學科：藥學 2區；在JCR（Journal Citation Reports）分區等級為Q1。該刊發文范圍涵蓋藥學等領域，旨在及時、準確、全面地報道國內外藥學工作者在該領域取得的最新研究成果、工作進展及學術動態、技術革新等，促進學術交流，鼓勵學術創新。2021年影響因子為6.498，平均審稿速度較慢,6-12周。
| 大類學科 | 分區 | 小類學科 | 分區 | Top期刊 | 綜述期刊 |
| 醫學 | 2區 | PHARMACOLOGY & PHARMACY 藥學 | 2區 | 否 | 是 |
| JCR分區等級 | JCR所屬學科 | 分區 | 影響因子 |
| Q1 | PHARMACOLOGY & PHARMACY | Q1 | 6.498 |
| 影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開放訪問 | 平均審稿速度 |
| 6.498 | 94 | 10.13% | 38.14% | 未開放 | 較慢,6-12周 |
課題、SCI/EI/SSCI怎么寫？